On May 27, the Shenzhen Stock Exchange issued a regulatory letter on Weikang Pharmaceutical and related parties. According to the regulatory letter, on April 29, 2024, the “2023 Annual Report” disclosed by the company showed that the company achieved net profit attributable to shareholders of listed companies in 2023 of -8.0386 million yuan. The company failed to forecast performance within one month from the end of the fiscal year in accordance with regulations. The above actions of the company violated the regulations of the Shenzhen Stock Exchange. Liu Zhongliang, then chairman of the company, Kong Xiaoxia, general manager at the time, Zhu Ting, secretary of the board of directors, and Wang Jing, financial director, failed to perform their duties with due diligence, and were responsible for the company's irregularities.
未按规定在会计年度结束之日起1个月内进行业绩预告，维康药业及时任董事长等收深交所监管函
Performance forecasting was not carried out within 1 month from the end of the fiscal year in accordance with regulations. Weikang Pharmaceutical received a regulatory letter from the Shenzhen Stock Exchange when it was appointed as chairman, etc.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated